Boston Scientific Co. (NYSE:BSX) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 4,914,442 shares of the medical equipment provider’s stock after acquiring an additional 22,621 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Boston Scientific were worth $438,979,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. M&T Bank Corp raised its position in Boston Scientific by 0.3% in the third quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider’s stock valued at $8,894,000 after purchasing an additional 370 shares during the period. Passumpsic Savings Bank acquired a new position in Boston Scientific in the third quarter valued at about $3,015,000. World Investment Advisors LLC boosted its stake in Boston Scientific by 50.9% during the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider’s stock worth $979,000 after buying an additional 3,939 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Boston Scientific during the third quarter valued at about $1,175,000. Finally, Tidal Investments LLC increased its position in shares of Boston Scientific by 8.8% during the third quarter. Tidal Investments LLC now owns 86,507 shares of the medical equipment provider’s stock valued at $7,249,000 after acquiring an additional 6,990 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $95.08 on Friday. The business has a 50 day moving average price of $99.46 and a 200 day moving average price of $94.41. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market cap of $140.63 billion, a price-to-earnings ratio of 76.06, a PEG ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research analyst reports. Truist Financial lowered their price objective on shares of Boston Scientific from $120.00 to $113.00 and set a “buy” rating for the company in a research report on Friday, April 11th. UBS Group raised their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Morgan Stanley boosted their price objective on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Argus set a $130.00 target price on Boston Scientific in a report on Tuesday, February 18th. Finally, Barclays boosted their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and a consensus price target of $110.22.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 133,183 shares of company stock worth $13,948,476. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.